Based on a previously derived population pharmacokinetic model, a novel neonatal 26 amikacin dosing regimen was developed. The aim of the current study was to 27 prospectively evaluate this dosing regimen. First, early (before and after second dose) 28 therapeutic drug monitoring (TDM) observations were evaluated for achieving target 29 trough (<3 mg/L) and peak (>24 mg/L) levels. Secondly, all observed TDM 30
INTRODUCTION 50
Despite profound differences between neonates and adults, neonatal dosing regimens are 51 usually derived from adult regimens using extrapolations based on bodyweight. However, 52
this may lead to under-or overdosing (1,2). To establish evidence-based dosing regimens 53 for neonates, population specific pharmacokinetic (PK) data are needed (3). Non-linear 54 mixed effect (NLME) modeling is a tool to generate this knowledge and to improve drug 55 dosing regimens. A crucial, but often missing part in the development of model-derived 56 dosing regimens is a subsequent thorough evaluation and validation of these dosing 57 regimens in a large prospective clinical study (3). 58
The aminoglycoside amikacin is entirely eliminated by glomerular filtration. The increase 59 in amikacin clearance in early life hereby reflects maturation of glomerular filtration rate 60 (GFR) (4). Amikacin is commonly recommended to treat (suspected) neonatal sepsis. In 61 our department, co-treatment with amoxicillin (early-onset cases) or vancomycin (late-62 onset cases) is prescribed. Despite the frequent use of amikacin, currently used dosing 63 regimens may lack efficacy or systematically reach the toxic range (4) Moreover, the distribution of the data points around the line of unity of the observed 227 versus predicted plot indicates that the interindividual variability is both acceptable and 228 similar across the entire neonatal population. This is also reflected in Figure S1 in which 229 the interindividual variability on clearance is plotted against birth bodyweight, postnatal 230 age and co-administration of ibuprofen. Figure S1 illustrates that the pharmacokinetic 231 model of amikacin is able to describe the prospective dataset accurately across the 232 different covariates as no trend is seen in the interindividual variability on clearance 233 versus these covariates. This result was obtained despite the fact that there were small 234 differences in clinical characteristics between the dataset that was used to build the model 235 (4) and the prospective dataset. Table 3 gives an overview of the parameter estimates of 236 the recently published final pharmacokinetic model (4) together with the parameter 237 estimates obtained for the current prospective dataset. Based on the values in Table 3 
Monte Carlo simulations 245
Monte Carlo simulations were performed to illustrate the exposure to amikacin in two 246 times 5000 neonates (with and without ibuprofen administration) following the simplified 247 model-based and the original model-based dosing regimen (4) after 5 consecutive doses. 248
In Table 4a Table 1 , for the simplified dosing regimen and the original dosing regimen (4) 263 respectively (Table 4a and (Table 4a and 
4b). 314 315
Besides the overall positive evaluation of the model-based dosing regimen, we anticipate 316 that the exposure for some patient groups can be further improved. Considering observed 317 trough levels, group 7 (current weight 2000-2800g, PNA<14 days) and 9 (current weight 318 >2800g, PNA<14 days), had a relevant proportion of early trough observations 319 (respectively 50% and 41%) between 3-5 mg/L, and this elevated incidence was also 320 confirmed in the Monte Carlo simulations (Table 4a and 4b) after 4-5 administrations 321 (steady state). In the setting of peak levels on target, this indicates that an additional 322 interval prolongation (+6h) for the subgroups 7 and 9 may be of additional benefit to 323 avoid toxicity. We therefore suggest a further adapted dosing regimen for these 324 subgroups. Since optimal peak concentrations are achieved using the simplified model-325 based dosing regimen, the 15 mg/kg dose can remain the same, but an interval of 36h 326 instead of 30h, and 30h instead of 24h, for respectively group 7 and 9 can be considered, 327 as suggested in Table 1 between the original and current dataset, this evaluation step is important. Moreover, the 338 covariates birth bodyweight, postnatal age and co-administration of ibuprofen are 339 correctly implemented on clearance as no trend is seen when plotting the interindividual 340 variability on clearance versus the different covariates ( Figure S1 ). When evaluating 341 Figure 1 and Figure S1 we concluded that only random variability remained in the model. 342 343 Finally, we also explored remaining causes of impaired amikacin exposure predictability. 344
First of all, prescription errors were evaluated. In the current study, the extent of 345 suboptimal early trough and peak amikacin levels associated with prescription errors 346 (8.5% and 10.8% respectively) is in line with the extent of overall prescription errors 347 (9.1%) in the prospective dataset, suggesting that this is not a major cause of unexplained 348 variability per se. Overall, drug prescription errors are common and multifactorial. 547 548 Table 4 : The percentage of individuals of subgroups 1-10 as defined in Table 1 was not co-administered (Table 4a ) and when ibuprofen was co-administered (Table 4b) 
